IP Library Granted Patent US 10,814,092
Granted Patent B2
US 10,814,092 · App. 16/186,790 · Granted Oct 27, 2020

Conversion of nitrogen dioxide (NO

Inventors: David P. Rounbehler (Lexington, MA); David H. Fine (Cocoa Beach, FL)
Assignee: VERO Biotech LLC
A61M16/12A61D7/04A61M16/0057A61M16/10A61M16/104C01B21/24A61M15/00A61M2016/102A61M2202/0275
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,814,092
App. No.
16/186,790
Granted
Oct 27, 2020
Kind
B2
Abstract

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Claims (17)

1. A method of delivering nitric oxide to a human comprising converting nitrogen dioxide to nitric oxide by fluidly communicating a gas flow including nitrogen dioxide to a receptacle including an inlet, an outlet, and a surface-active material comprising silica coated with an aqueous solution of an antioxidant, wherein the antioxidant includes ascorbic acid or a variant of vitamin E, wherein the inlet is configured to receive the gas flow and fluidly communicate the gas flow to the outlet through the surface-active material such that nitrogen dioxide in the gas flow is converted to nitric oxide.

2. The method of claim 1 wherein the surface-active material is saturated with the aqueous solution of the antioxidant.

3. The method of claim 1 wherein the surface-active material comprises a substrate that retains water.

4. The method of claim 1 wherein the variant of vitamin E includes alpha tocopherol or gamma tocopherol.

5. The method of claim 4 where the silica gel is 35 to 70 sized mesh.

6. The method of claim 1 wherein the receptacle comprises a cartridge.

7. The method of claim 1 wherein the antioxidant comprises ascorbic acid.

8. The method of claim 1 wherein the receptacle is at ambient temperature.

9. The method of claim 1 wherein the surface-active material is prepared using a solution of ascorbic acid in water.

10. The method of claim 9 wherein the surface-active material is prepared using a 20% solution of ascorbic acid in water.

11. The method of claim 9 wherein the surface-active material is prepared using a 25% solution of ascorbic acid in water.

12. The method of claim 9 wherein the surface-active material is prepared using a 30% solution of ascorbic acid in water.

13. The method of claim 1 wherein the surface-active material is prepared by soaking the surface-active material in a solution of ascorbic acid in water and air drying the surface-active material before inserting the surface-active material into the receptacle.

14. The method of claim 1 wherein the surface-active material is prepared by soaking the surface-active material in a solution of ascorbic acid in water and drying the surface-active material with a gas before inserting the surface-active material into the receptacle.

15. The method of claim 1 wherein the antioxidant comprises alpha tocopherol or gamma tocopherol.

16. The method of claim 1 wherein the receptacle includes screen and glass wool adjacent to both the inlet and the outlet.

17. The method of claim 1 wherein the screen and glass wool is soaked in the aqueous solution of antioxidant before being inserted in the receptacle.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: CYTERRA CORPORATION
To: GENO LLC
Reel/Frame 052928/0976 →
CHANGE OF NAME Recorded Jun 12, 2020
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 052932/0266 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: ROUNBEHLER, DAVID R.; FINE, DAVID H.
To: CYTERRA CORPORATION
Reel/Frame 052928/0989 →
Cited By (6)
US 12,509,349 US 12,522,501 US 12,569,628 US 12,576,234 US 12,606,436 US 12,661,477